Table 6. Adverse effects from the Japan cohort study resulting in dose changes or withdrawal from treatment.

Adverse effect (>Grade 3)	Number of patients	Patients who required dose reduction (%)	Patients who withdrew from treatment (%)
Hepatobiliary problems	206	62.6	31.6
Gastrointestinal problems	178	48.9	24.7
Respiratory, thoracic, and mediastinal problems	121	12.4	76.9
Metabolism and nutrition problems	96	41.7	29.2
Infections	94	44.7	38.3
Blood and lymphatic problems	78	52.6	10.3
Nervous system problems	27	40.7	37
Neoplasms	21	4.8	71.4
Cardiac problems	21	42.9	42.9